期刊文献+

疏肝导浊方药治疗非酒精性脂肪肝的临床研究 被引量:8

Treating Non-alcohol Fatty Liver with Shugan Daozhuo Prescription
下载PDF
导出
摘要 [目的]观察疏肝导浊方药对脂肪肝患者的临床症状、脂质代谢和肝、肾功能的影响。[方法]临床随机选取72例脂肪肝患者服用疏肝导浊方药3个月,服药前与服药后自身对照观察临床症状,进行药物有效率处理;服药前与服药后3个月的血糖(BG)、甘油三酯(TG)、胆固醇(TC)、谷丙转氨酶(ALT)、尿素氮(BUN)和肌酐(Cr)结果采用随机区组设计方差分析进行统计处理。[结果]疏肝导浊方药可以降低血清中BG、TG、TC和ALT的含量(P<0.01),对BUN和Cr的含量没有影响(P>0.05);服药前、后自身对照临床症状观察总有效率为67%。[结论]疏肝导浊方药可促进脂肪肝患者血糖血脂和ALT酶活性的降低,促进脂质代谢,恢复肝功能,治疗脂肪肝,并且在患者服药3个月中尚未发现肾脏损害。 [Objective]To observe the effects of Shuogandaozhuo(Dispersing the stagnated liver QI and Reducing the turbid pathogen)medicine(SM)on patient with fatty liver,including clinic symptom,lipid metabolism and hepatic,nephric function.[Method]Seventy-two patient with fatty liver were randomly enrolled and treated with Shuogandaozhuo medicine for 3 months.Before and after treatment selfcomparisons were performed on the clinic symptom,BG,TG,TC,ALT,BUN,Cr.[Results]Shuogandaozhuo medicine could reduce the serum BG,TG,TC and ALT levels of patient with fatty liver(P 0.01).No effect was found on the content of BUN,Cr levels.[Conclusion]SM can promote the reducing of blood glucose and lipid levels and serum ALT activity.
出处 《天津中医药大学学报》 CAS 2010年第3期123-125,共3页 Journal of Tianjin University of Traditional Chinese Medicine
关键词 脂肪肝 疏肝导浊方药 胆固醇 甘油三酯 fatty liver Shugandaozhuo Medicine cholesterol triglyceride
  • 相关文献

参考文献5

二级参考文献15

  • 1范建高 曾民德 等.上海市4009名机关职员脂肪肝流行病学调查[J].中华肝脏病杂志,1998,6(1):17-17. 被引量:34
  • 2[1]Marchesini G,Brizi M,Bianchi G,et al.Nonalcoholic fatty liver disease: a feature of the metabolic syndrome[J].Diabetes,2001,50(8):1844-1850. 被引量:1
  • 3[2]Matthews D R,Hosker J P,Rudenski A S,et al.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man[J].Diabetologia,1985,28(7):412-419. 被引量:1
  • 4[3]Cortez-Pinto H,Chatham J,Chacko C P,et al.Alterations in liver ATP homemostasis in human nonalcoholic steatohepatitis:a pilot study[J].JAMA,1999,282(17):1659-1664. 被引量:1
  • 5[4]Sheth S G,Gordon F D,Chopra S.Nonalcoholic steatohepatitis[J].Ann Intern Med,1997,126(2):137-145. 被引量:1
  • 6[5]Paul A.Nonalcoholic Fatty Liver Disease[J].N Engl J Med,2002,346(16):1221-1231. 被引量:1
  • 7[6]Kumar K S,Malet P F.Nonalcoholic steatohepatitis[J].Mayo Clin Proc,2000,75(7):733-739. 被引量:1
  • 8[7]Marchesini G,Brizi M,Morselli-Labate AM,et al.Association of nonalcoholic fatty liver disease with insulin resistance[J].Am J Med,1999,107(5):450-455. 被引量:1
  • 9[8]Tilg H,Diehl A M.Cytokines in alcoholic and nonalcoholic steatohepatitis[J].N Engl J Med,2000,343(20):1467-1476. 被引量:1
  • 10[9]Moller D E.Potential of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes[J].Trend Endocrinol Metab,2000,11(6):212-217. 被引量:1

共引文献150

同被引文献82

引证文献8

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部